These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation. Lip GY; Frison L; Grind M; J Intern Med; 2008 Jul; 264(1):50-61. PubMed ID: 18266660 [TBL] [Abstract][Full Text] [Related]
27. Will this be the end of the anticoagulation clinic for patients with atrial fibrillation? Mitchell AR Curr Drug Targets Cardiovasc Haematol Disord; 2005 Oct; 5(5):405-8. PubMed ID: 16248832 [TBL] [Abstract][Full Text] [Related]
28. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study. Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184 [TBL] [Abstract][Full Text] [Related]
29. Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. Rockson SG; Albers GW J Am Coll Cardiol; 2004 Mar; 43(6):929-35. PubMed ID: 15028346 [TBL] [Abstract][Full Text] [Related]
30. Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor. Halperin JL Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):163-74. PubMed ID: 15151465 [TBL] [Abstract][Full Text] [Related]
31. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456 [TBL] [Abstract][Full Text] [Related]
32. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? Go AS; Hylek EM; Chang Y; Phillips KA; Henault LE; Capra AM; Jensvold NG; Selby JV; Singer DE JAMA; 2003 Nov; 290(20):2685-92. PubMed ID: 14645310 [TBL] [Abstract][Full Text] [Related]
33. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting. Agarwal S; Bennett D; Smith DJ Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933 [TBL] [Abstract][Full Text] [Related]
34. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. Larsen TB; Rasmussen LH; Gorst-Rasmussen A; Skjøth F; Lane DA; Lip GY Am J Med; 2014 Dec; 127(12):1172-8.e5. PubMed ID: 25193361 [TBL] [Abstract][Full Text] [Related]
35. Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified? Baruch L; Gage BF; Horrow J; Juul-Möller S; Labovitz A; Persson M; Zabalgoitia M Stroke; 2007 Sep; 38(9):2459-63. PubMed ID: 17673721 [TBL] [Abstract][Full Text] [Related]
36. Efficacy of anticoagulation for secondary stroke prevention in older people with non-valvular atrial fibrillation: a prospective case series study. Tsivgoulis G; Spengos K; Zakopoulos N; Manios E; Peppes V; Vemmos K Age Ageing; 2005 Jan; 34(1):35-40. PubMed ID: 15591481 [TBL] [Abstract][Full Text] [Related]
37. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196 [TBL] [Abstract][Full Text] [Related]
38. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. White HD; Gruber M; Feyzi J; Kaatz S; Tse HF; Husted S; Albers GW Arch Intern Med; 2007 Feb; 167(3):239-45. PubMed ID: 17296878 [TBL] [Abstract][Full Text] [Related]
39. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM; Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720 [TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective. Chevalier J; Delaitre O; Hammès F; de Pouvourville G Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]